

1 **Antimicrobial resistance patterns of bacterial isolates from bloodstream**
2 **infections at Jinja regional referral hospital: A cross-sectional study**

3
4 **Fahad Lwigale** ^{1,2*}

5
6 ¹Global Health Security Program, Infectious Diseases Institute, College of Health Sciences,
7 Makerere University, Kampala, Uganda;

8
9 ²Jinja Regional Referral Hospital, Jinja, Uganda

10
11 *Corresponding author

12 Email: fahadlwigale@gmail.com (FL), flwigale@idi.co.ug (FL)

13
14
15
16
17
18
19
20
21
22
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

Introduction

Bloodstream infections are a commonly encountered clinical syndrome of public health concern with variable epidemiology. The characteristic of resistance to multiple antibiotics by their etiologic agents has limited the options for empirical sepsis case management. This study determined the most frequent aetiologic agents responsible for bloodstream infections, their antimicrobial susceptibility patterns, and infection sources in Eastern-Central Uganda.

Materials and methods

This retrospective study involved analysis of all non-duplicate blood culture reports from 2019 to 2021. The frequency and percentage of significant pathogenic organisms and contaminants were calculated. Positivity distribution including infection sources was determined. World Health Organization Network (WHONET) 2022 desktop software was used for antimicrobial susceptibility data analysis.

Results

The 1364 participants had a diagnostic yield of 114(6.8%) and a 1.5% contamination rate. Over 37% and 13% of infections were hospital and community-acquired respectively. Most etiologic agents were Gram-positive bacteria dominated by *Staphylococcus aureus* 39(34.2%). Gram-negatives mainly included unspecified *Coliforms* 12(10.5%), and *E. coli* 10(8.8%). Polymicrobial growth existed in 4(0.3%) cases. *S. aureus* was mainly resistant to Penicillin G (100%), Cefoxitin (60%), and Erythromycin (52.2%). Both *Escherichia coli* and unspecified *coliforms* showed high resistance to Ampicillin (87.5%) and third-generation Cephalosporins (100%). The least resistance was to Chloramphenicol and Carbapenems.

Conclusion

BSIs are mainly due to Gram-positive bacteria. Suspected sepsis cases by *S. aureus* in this region can be empirically managed using Gentamicin. Microbiology services should be routinely utilized to guide antimicrobial use, monitor blood culture contamination rates and resistance trends to strengthen regional antimicrobial stewardship.

Introduction

Bloodstream Infections (BSIs) are some of the most commonly encountered and serious Healthcare-Associated Infections (HAIs) of public health concern(1-3). This results from microorganisms accessing the bloodstream where they reproduce and excrete toxins during septicemia (4). It is characterized by a number of symptoms including fever ($>38^{\circ}\text{C}$), chills, hypotension, tachypnea, hypothermia ($<36^{\circ}\text{C}$), apnea, or bradycardia depending on different factors including the age group (2, 5). A Bloodstream Infection (BSI) is confirmed by a positive blood culture in the microbiology laboratory whether primary or secondary (1, 2, 6). A primary BSI is a laboratory-confirmed positive blood culture without any link to another infected body site (5). A secondary BSI on the other hand involves the isolation of an organism within a 14-17-day period from the bloodstream with the same identity as one responsible for another existing body site-specific infection or contributes to a syndrome (5). This can be a urinary tract infection (UTI), respiratory tract infection (RTI), or skin and soft tissue infection (SSTI) among others.

Among all ages, BSIs are one of the major causes of morbidity and mortality in both developed and developing countries (7, 8). In the United States of America (USA), they are the 11th leading cause of mortality and among the top seven causes of death in Europe (9). Among febrile neutropenic patients, 6% of deaths are due to BSIs (10). They cause 13-15%

70 of deaths in case of neonatal sepsis and 30-50% of deaths in developing countries (7). The
71 mortality rate is 33.3% -46.9% in Italy (2). Among cancer patients, BSIs are responsible for
72 a death rate of 24% and 33% in developed and then low- and middle-income countries (LMIC)
73 respectively (11). As an emergency condition, sepsis requires immediate detection and
74 identification of the causative agent for proper treatment in the current era of the
75 Antimicrobial Resistance (AMR) silent pandemic(1, 12). For this matter, blood culture testing
76 is an important tool for the diagnosis of BSIs and AMR surveillance at large(4, 6, 13).

77 Pathogen Recovery from the blood cultures has been observed to vary in Asia and Africa with
78 comparable levels ranging from 6.11% to 27.1% (3, 10, 14-16). It was as high as 71% in
79 Ethiopia (17). East African levels are 11.71% to 14.2% (18, 19). Uganda has previously been
80 reported to have a diagnostic yield of 4.6% with 2.6% for Jinja (13). However, up to 14.1%
81 positivity has been observed among cancer patients (11). The majority of studies unanimously
82 report males to be the major victims of the BSIs ranging from 60.4% to 65% (2, 4, 9, 20). The
83 majority belonged to 18-88 years of age (9, 20). BSIs of hospital origin have been reported to
84 range between 10% to 81.5% (2, 4, 8). Community-acquired BSIs have also been reported to
85 be as high as 91.1% to 91.6% elsewhere(14, 21).

86 Geographic and epidemiological factors have resulted in differences in the profile of BSIs
87 observed(2, 8, 9, 11, 12). Gram-negative organisms have been reported to be dominant in
88 some areas (11, 12, 15, 19, 22). ESKAPE composed of *Enterococcus faecium*, *Staphylococcus*
89 *aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas*
90 *aeruginosa*, and *Enterobacter species* altogether contributes up to 70% of the observed BSIs
91 (23). This is dominated by *E. coli*, *K. pneumoniae*, *S. epidermidis*, and *S. aureus* (23). Many
92 others are similar to that (9, 12). Other studies indicate Gram-positive bacteria especially
93 *Staphylococcus species* and *Enterococcus species* to be of a higher frequency(3, 4, 17, 20).
94 AMR priority pathogens including *Staphylococcus aureus* (54%), *Escherichia coli* (19%),

95 *Salmonella species* (11%), *Streptococcus pneumoniae*, and *Klebsiella species* (5%) were
96 previously reported as the most dominant in Uganda (13).

97 Variably high resistance levels have been reported for multiple antibiotics including
98 Gentamicin, Cephalosporins, and Carbapenems among *Enterobacterales* and *Acinetobacter*
99 *baumannii* (9, 11, 18). There is an exhibition of different resistance phenotypes with levels
100 up to 28.9% of Methicillin-Resistant *S. aureus* (MRSA), 23.9% of Extended-spectrum beta-
101 lactamase (ESBL) producers while the Carbapenem-resistant (CarbR) are up to 26.3% (2). In
102 Uganda, up to 57.1% resistance to Imipenem is reported (11). The majority of isolates have
103 been observed to be more susceptible to Meropenem, Amikacin, Piperacillin/Tazobactam,
104 and Ciprofloxacin (9, 12, 17, 24). These infections are commonly empirically managed using
105 a combination of broad-spectrum intravenously administered antibiotics such as Ceftriaxone
106 and Metronidazole. However, empirical therapy has been reported to facilitate the emergence
107 of Antimicrobial resistance(7, 25). In this case, microorganisms can thrive in an environment
108 composed of an antimicrobial agent previously capable of killing it or preventing its
109 reproduction. Bacterial isolates of this nature have been associated with bloodstream
110 infections (BSIs) where they exhibit Multi-Drug Resistant (MDR) phenotypes such as the
111 Methicillin Resistant *Staphylococcus aureus* (MRSA), Extended Spectrum Beta Lactamase
112 (ESBL) producers and Carbapenem-resistant (CarbR) organisms (2, 7, 18). This increases the
113 possibility of therapy failure, longer hospital-stay periods with increased risk of acquisition
114 of more infections, high healthcare costs, and a higher risk of death (9, 10, 25).

115 Despite the setup of the Medicines and Therapeutic Committee (MTC) and the Infection
116 Prevention and Control (IPC) committees at Jinja regional referral hospital (Jinja RRH) by
117 the ministry of health (MoH) of Uganda and implementing partners such as the Infectious
118 Diseases Institute (IDI), there is a shortage of congregated up-to-date information to guide the
119 choice of antibiotics for empirical therapy to ensure better control of antimicrobial use and

120 consumption in the region served by the facility. This is in addition to a shortage in
121 microbiology services as this site is the only supplier in the region and yet it is also affected
122 by other factors including a shortage of supplies and staff resulting in intermittent availability
123 of information for targeted therapy of bloodstream infections. The ever-changing
124 microbiological profile of BSIs and the lack of published literature about this region makes it
125 necessary to routinely generate, analyze and utilize the local data about infectious syndromes.
126 This study aimed at determining the levels and distribution of the main causative agents for
127 BSIs at Jinja RRH, their antibiotic profiles and major sources of the infections. This was well
128 achieved. It will in turn help physicians, MTC, IPC committees, and policymakers to
129 formulate guidelines for the management of BSIs, better infection prevention and control, and
130 improve the antimicrobial stewardship and surveillance activities in Jinja RRH and the
131 Eastern-Central region of Uganda.

133 **Materials and methods**

134 **Operational definition**

135 A Bloodstream Infection (BSI) refers to a positive blood culture test due to isolation of a
136 significant pathogenic microorganism/s from the suspected patient's blood sample. The
137 organism can be bacterial or fungal in nature.

139 **Study design, setting, and population**

140 This was a retrospective cross-sectional study conducted in 2022 using data generated over a
141 two-and-a-half-year period from January 2019 through June 2021. This period was shortly
142 after the stabilization of microbiology service delivery in the region. The Corona Virus
143 Disease-2019 (COVID-19) pandemic was experienced in the same time zone and significantly

144 impacted health service delivery. The data was collected at Jinja regional referral hospital.
145 This is a 500-bed capacity hospital located along Bax Street within the central town of Jinja
146 city in the Eastern-Central part of Uganda. As a referral hospital, this facility serves a
147 population of approximately 4.5 million people from within Jinja and the surrounding areas
148 of over 11 districts including Iganga, Mayuge, Kamuli, Buikwe, Lugazi, Kayunga, and
149 Mukono districts.

150 The facility is equipped with a microbiology laboratory where examinations of various
151 samples are conducted for routine patient care and management. Blood culture was carried
152 out using the BD-BACTEC™ FX40 (BacT/ALERT) automated system. Organism
153 identification was carried out using conventional methods up to the genus and species levels.
154 Antimicrobial susceptibility testing was carried out using the Kirby-Bauer disk diffusion
155 method following the Clinical and Laboratory Standards Institute (CLSI) guidelines; CLSI-
156 2018-M100-S28(26), CLSI-2020-M100-S30(27) and CLSI-2021-M100-S31 (28). There
157 were different antibiotic categories tested as commonly used against different organisms. The
158 Penicillins included Penicillin G (10 units), Ampicillin(10µg), and Piperacillin (100µg).
159 Cephalosporins included Ceftriaxone (30µg), Cefotaxime (30µg), Cefuroxime(30µg),
160 Ceftazidime(30µg) and Cefoxitin (30µg). Combinations included Amoxicillin/Clavulanate
161 (20/10)µg and Trimethoprim/Sulfamethoxazole(Co-trimoxazole) (1.25/23.75)µg.
162 Erythromycin(15µg) was tested among the Macrolides. Carbapenems involved Imipenem
163 (10µg), Meropenem (10µg) and Ertapenem (10µg). Fluoroquinolones mainly included
164 Ciprofloxacin(5µg). The Lincosamide tested was Clindamycin (2µg). Aminoglycosides
165 included Gentamicin (10µg) and Amikacin (30µg). Tetracycline and Chloramphenicol of
166 composition 30µg each were also included.

167 This study aimed to determine the level of bloodstream infections and their common etiological
168 agents; the percentage resistance and/or sensitivity of the etiological agents to common

169 antibiotics; and the levels of community and healthcare-associated infections. A sample size
170 of 410 participants was estimated using a 5% prevalence and a precision of 0.021 at 95%
171 confidence. However, data from all patients (1364) with suspected BSI and non-duplicate
172 blood culture tests carried out during the study period was considered. The higher sample size
173 was aimed at increasing the chances of obtaining the minimum of thirty (30) isolates
174 necessary to generate reliable cumulative antibiograms according to CLSI-M39A4E-2014
175 (29). This together was to increase precision and have a better representation of the population.
176

177 **Data Management**

178 The data necessary for the study was accessed in 2022 and extracted from the African
179 Laboratory Information System (ALIS) into an excel sheet. This was cleaned and anonymized
180 by removal specific identifiers such as patient names and numbers before being analyzed. All
181 sex types and age groups such as pediatrics, adolescents, and adults were included in the
182 analysis. Only the first isolate of every patient in the study time period was included in the
183 analysis to generate the antimicrobial susceptibility patterns as guided by CLSI-M39A4E-
184 2014 (29). Organisms commonly found on the skin such as *Coagulase negative*
185 *staphylococcus*(CoNS), *Corynebacterium Species*, and *Bacillus species* other than *B.*
186 *anthracis* were treated as contaminants. The rest of the organisms were considered significant
187 aetiologic agents when calculating the frequencies and respective percentages.

188 Hospital and community-acquired infections were defined based on the duration of patient
189 hospitalization at the facility before sample collection. The infections diagnosed among
190 personnel admitted and exposed to the hospital premises for at least 48 hours (two days) were
191 treated as healthcare-associated (Hospital-acquired/Nosocomial) infections. Community-
192 acquired infections on the other hand involved personnel exposed to the premises of the
193 hospital for less than 48 hours. Respective frequencies and percentages were calculated.

Ethics Statement

The Jinja Hospital Research and Ethics Committee approved the study with registration number **JREC 159/2022**. The data was obtained from records of personnel who seek medical services at the facility. This is kept in medical records including patients files, laboratory request forms and information systems for proper care and later reference. The Microbiology Laboratory records were anonymously analyzed for this study and no consent was obtained from individual personnel.

Statistical analysis

Microsoft Excel (2016) was used for data cleaning and descriptive analysis. World Health Organization Network (WHO-NET 2022) desktop software was used to analyze the antimicrobial susceptibility data. Only the first isolate of every participant was involved in generation of antimicrobial susceptibility profiles. These were presented as percentage resistance and/or sensitivity/susceptibility. Results including positivity distributions, hospitalization history, organisms/aetiologic agents and AST data were presented in the form of frequencies and percentages in different tables and figures. There was a description of their distribution in socio-demographics including age, sex, and location (wards).

Results

A total of 1364 participants were involved in the analysis. 800(58.7%) were male while females were 564(41.3%). The majority (86.2%) of participants were less than 12 years of age. A total of 114(8.4%) blood samples were positive. Of these, 93 had significant growth representing a true diagnostic yield of 6.8% as shown in **Fig 1**.

Fig 1. Levels of positivity for blood cultures. The observed prevalence of bloodstream infections is 6.8%.

The contamination rate observed was 1.5%. (Refer to **Table 1** for details). Positivity was observed more among the males 67(58.8%) than the females 47(41.2%) (**Table 1**). The frequency and percentage of isolated organisms are illustrated in **Fig 2**. Of the 114 positive cases, 68(60.0%) were Gram-positive bacteria while 44(38.6%) were Gram-negative. *Candida species* represented the remainder.

Fig 2. Frequency and Percentage of Isolated Organisms.

Table 1. Positivity distribution in the different population groups.

Growth		Significant	Contaminant	NBG	Total
Frequency	n	93	21	1250	1364
Percentage	%	6.8	1.5	91.6	100

Gram Reaction n(%)	Positive	49(70)	21(30)	N/A	70
	Negative	44(100)	0(0)	N/A	44
Sex n(%)	Male	54(6.8)	13(1.6)	733(91.6)	800
	Female	39(6.9)	8(1.4)	517(91.7)	564
Age Group n(%)	≤12	78(6.6)	18(1.5)	1080(91.8)	1176
	13-18	4(9.1)	0(0)	40(90.9)	44
	19-35	2(3.3)	0(0)	58(96.7)	60
	36-59	5(9.4)	2(3.8)	46(86.8)	53
	≥ 60	4(12.9)	1(3.2)	26(83.9)	31
Ward n(%)	OPD	1(4.3)	0(0)	22(95.7)	23
	A&E	3(7.7)	0(0)	36(92.3)	39
	Pediatric	75(6.6)	18(1.6)	1043(91.8)	1136
	Medical	3(5.9)	2(3.9)	46(90.2)	51
	ICU	0(0)	0(0)	8(100)	8
	Others	11(10.3)	1(0.9)	95(88.8)	107
Total		93(6.8)	21(1.5)	1250(91.6)	1364

240 A&E, Accidents and Emergency; ICU, Intensive Care Unit; NBG, No Bacterial Growth; N/A, Not
241 Applicable; OPD, Outpatient Department
242
243

244 Gram positive bacteria majorly included, *Staphylococcus aureus* 39(34.2%), *Coagulase*
245 *negative staphylococcus* 20(17.5%) then *Streptococcus species* 7(6.1%). Gram-negative
246 bacteria on the other hand were made of general unspecified *Coliforms* 12(10.5%), *E. coli*
247 10(8.8%), *Klebsiella species* 5(4.4%), *Acinetobacter species* 4(3.5%), *Pseudomonas*
248 *aeruginosa* 3(2.6%), then *Salmonella species* 2(1.8%). Other organisms included *Candida*
249 *albicans*, *Enterobacter*, *Serratia*, *Citrobacter*, and *Shigella species*. Most cases were observed
250 in the pediatric unit among children less than 13 years of age. Polymicrobial growth was

251 observed in 4(0.3%) cases of which two involved a *Serratia species* and one had a *Bacillus*
252 *species* in addition to the co-isolates.

253
254
255 Percentage resistance among *S. aureus* isolates is shown in **Fig 3**. Among *E. coli* and
256 unspecified *coliform* isolates combined(n=22), Percentage resistance to Ampicillin,
257 Cefuroxime, Ceftazidime, Cefotaxime, Gentamicin, Ciprofloxacin, Imipenem, Ertapenem,
258 Co-trimoxazole, Tetracycline, and Chloramphenicol was 87.5%, 100%, 100%, 100%, 50%,
259 50%, 20%, 33.3%, 66.7%,60%, and 28.6% respectively. *Non-Enterobacterales* (*P.*
260 *aeruginosa* and *A. baumannii*) together(n=7) had the following resistance profile;
261 Ceftazidime (20%), Aztreonam (50%), Imipenem (0%), Meropenem (50%), Gentamicin
262 (40%), Ciprofloxacin (33.3%) and Tetracycline (0%).

263
264 **Fig 3: Percentage resistance for *Staphylococcus aureus* to common antibiotics.**

265
266 **Table 2** shows the total number of different isolates and respective proportions tested against
267 the antibiotics. Further, respective frequencies for the Resistant(R), Intermediate(I), and
268 Susceptible(S) categories as outcomes of the antimicrobial susceptibility test (AST) reporting
269 format have been revealed. This details the ratio of organism to antibiotic tested with
270 respective outcomes compared with the number of organisms isolated.

Table 2. Frequency and percentage of organisms tested against different antibiotics

Antibiotic	AST Result	Name of Organism																	
		S. aureus n =39		Strepto coccus Species n =7		Coliforms (Unspecified) n =12		E. coli n =10		Klebsiella Species n =5		Acinetobacter Species n =4		P. aeruginosa n =3		Salmonella & Shigella Species n =3		Others n = 11	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	% ^a	n	%
Ampicillin	R	-	-	-	-	2	16	5	50	3	60	-	-	-	-	2	60	-	-
	I	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
	S	-	-	-	-	1	8	0	0	0	0	-	-	-	-	0	0	-	-
Penicillin G	R	6	15	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	I	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	0	0	1	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piperacillin	R	-	-	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-
	I	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
	S	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
	R	3	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cefoxitin	I	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	2	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cefuroxime	R	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	1	9
	I	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	0	0
	S	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	0	0
Ceftazidime	R	-	-	-	-	-	-	4	40	1	20	-	-	0	0	-	-	2	18
	I	-	-	-	-	-	-	0	0	0	0	1	25	0	0	-	-	0	0
	S	-	-	-	-	-	-	0	0	0	0	0	0	2	60	-	-	0	0
Cefotaxime	R	-	-	-	-	2	16	2	20	1	20	-	-	-	-	1	30	-	-
	I	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
	S	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
Ceftriaxone	R	-	-	-	-	-	-	2	20	2	40	-	-	-	-	-	-	1	9
	I	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	0	0
	S	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	0	0
Gentamicin	R	4	10	0	0	3	25	3	30	2	40	0	0	2	60	-	-	1	9
	I	3	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	9
	S	20	51	1	14	2	16	4	40	2	40	2	50	1	30	-	-	3	27

Amikacin	R	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-
	I	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-
	S	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-
Ciprofloxacin	R	6	15	0	0	6	50	3	30	2	40	2	50	0	0	0	0	2	18
	I	7	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	27
	S	16	41	1	14	3	25	6	60	3	60	1	25	3	100	3	100	1	9
Erythromycin	R	12	31	4	57	-	-	-	-	-	-	-	-	-	-	-	-	1	9
	I	2	5	1	14	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	S	9	23	2	57	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Meropenem	R	-	-	-	-	-	-	-	-	-	-	0	0	2	60	-	-	-	-
	I	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
	S	-	-	-	-	-	-	-	-	-	-	1	25	1	30	-	-	-	-
Imipenem	R	-	-	-	-	2	16	0	0	0	0	0	0	-	-	-	-	0	0
	I	-	-	-	-	1	8	0	0	0	0	0	0	-	-	-	-	0	0
	S	-	-	-	-	2	16	4	40	4	80	1	25	-	-	-	-	2	18
Etarpenem	R	-	-	-	-	1	8	0	0	0	0	-	-	-	-	1	30	0	0
	I	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	0	0

	S	-	-	-	-	0	0	2	20	1	20	-	-	-	-	0	0	1	9
Tetracycline	R	5	13	0	0	2	16	1	10	1	20	0	0	-	-	1	30	1	9
	I	4	10	1	14	1	8	0	0	0	0	0	0	-	-	0	0	0	0
	S	11	28	1	14	1	8	0	0	0	0	2	50	-	-	0	0	0	0
Clindamycin	R	3	8	2	28	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	I	2	5	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	17	44	1	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Chloramphenicol	R	2	5	0	0	1	8	1	10	3	60	-	-	-	-	-	-	3	27
	I	0	0	1	14	0	0	0	0	0	0	-	-	-	-	-	-	0	0
	S	4	10	1	14	1	8	4	40	0	0	-	-	-	-	-	-	1	9
Co-trimoxazole	R	-	-	-	-	0	0	2	20	2	40	-	-	-	-	0	0	2	18
	I	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	0	0
	S	-	-	-	-	1	8	0	0	0	0	-	-	-	-	1	30	1	9
Vancomycin	R	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	I	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	S	-	-	5	71	-	-	-	-	-	-	-	-	-	-	-	-	1	9
	R	-	-	-	-	-	-	-	-	1	20	-	-	1	30	-	-	1	9

Aztreonam	I	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	0
	S	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	0

272 AST, Antimicrobial Susceptibility Test; I, Intermediate; R, Resistant; S, Susceptible

273 ^aPercentages were calculated for isolates tested relative to the number of isolated organisms

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Table 3 shows the possible sources of infection in the different population groups for positive cultures. Altogether, 36.8% and 13.2% of the positive cases were hospital-acquired and community-acquired infections respectively. On a sad note, over 50% of the cases were of unknown origin.

Table 3. Likely infection source in the different population groups for positive cultures.

		Possible Source of Infection					
		Hospital		Community		Unknown	
		n	%	n	%	n	%
Overall		42	36.84	15	13.16	57	50.00
Sex	Male	25	37.3	9	13.4	33	49.3
	Female	17	36.2	6	12.8	24	51.1
Age Group	<12	36	37.5	10	10.4	50	52.1
	13-18	0	0.0	2	50.0	2	50.0
	19-35	1	50.0	1	50.0	0	0.0
	36-59	2	28.6	2	28.6	3	42.9
	>60	3	60.0	0	0.0	2	40.0
Ward	OPD	0	0.0	1	100.0	0	0.0
	A&E	1	33.3	1	33.3	1	33.3
	Pediatrics	35	37.6	9	9.7	49	52.7
	Medical	3	60.0	1	20.0	1	20.0
	ICU	0	0.0	0	0.0	0	0.0
	Others	3	25.0	3	25.0	6	50.0

295 A&E, Accidents and Emergency; ICU, Intensive Care Unit; NBG, No Bacterial Growth; OPD,
296 Outpatient Department

297 **Discussion**

298 The BSIs are known life-threatening conditions with variable levels distributed. These are
299 diagnosed when at least a single blood culture is carried out and a pathogenic microorganism
300 is isolated. This study obtained a significant positivity level of 6.8%. This is greater than 4.6%
301 and 2.6% for Uganda and Jinja respectively as earlier observed (13). This indicates an
302 improvement in pathogen recovery from blood cultures. Similar levels have been obtained in
303 other studies (14-16, 18). Variations of prevalence in different units have also been reported
304 focusing on different facilities (3). Other previous studies obtained a relatively higher
305 prevalence of up to 71% (17). This could be due to the study population of cancer patients
306 majority of whom were neutropenic and hence at a higher risk for the BSIs (17, 30).

307 The highest prevalence of positivity was observed among the pediatrics. This could be
308 explained by the low immune status of the children making them more vulnerable to the BSIs.
309 Also, the largest number of samples were from children. This calls for the need to improve
310 the infection prevention measures in these units. Routine blood culture is also recommended
311 among adults fitting the definition to contribute more data about adults regarding BSIs. Up to
312 91.6% of the blood cultures had no bacterial growth. This could be due to the prior use of
313 antibiotics between 1-28 days before blood culture testing as observed in many participants,
314 especially in the period starting from early 2020.

315 More males (58.8%) were observed to have the BSIs and this is in agreement with the majority
316 of previous studies(2, 4, 9, 20). Being male had also been associated with a high probability
317 of having a BSI (crude OR 2.8, 95% CI 0.69–6.5; P=0.042) (17).

318 Gram-positive bacteria (61.4%) were found to be more dominant compared to their Gram-
319 negative counterparts (38.6%). Previous studies obtained similar results (3, 4, 13, 17, 20).

320 Some research elsewhere also had differing observations where Gram-negatives were more
321 than Gram-positives (11, 12, 15, 18, 19, 22). More variability was also shown in the study
322 conducted in different ICUs (3). This provides a relatively larger tip of the iceberg regarding
323 the variation of dominant organism distribution which calls for local data analysis and
324 utilization.

325 *S. aureus* (34.2%) was the overall most commonly isolated organism at this site. The outcome
326 was also observed elsewhere (4, 13, 17). Among Gram-negatives, it was majorly unspecified
327 *Coliforms* (10.5%) followed by *E. coli* (8.8%) then *Klebsiella species* (4.4%), and
328 *Pseudomonas aeruginosa* (2.6%). This is comparable to observations by other studies (12,
329 23, 31). *CoNS* were also more frequently isolated in the pediatric samples than *Streptococcus*
330 *species* representing a contamination rate of 1.5% (21/1364). This was less than 13.6% and
331 4.8% observed at Princess Marina Hospital (PMH) and Tygerberg Hospital (TBH) neonatal
332 units in Sub-Saharan Africa (21). Other studies have also reported higher rates (2, 10, 11, 16,
333 20, 23). This could be due to the high likelihood of contamination in children's blood samples
334 during sample collection. However, the observed contamination rate falls within acceptable
335 limits ranging from 1-3% (6, 32). These isolates were not treated as true pathogens and no
336 AST was done on them. This is a good practise in order to avoid unnecessary use of antibiotics
337 in these children and their possible effects. On a sad note, only a single blood culture set was
338 commonly done for the different individuals. This is most likely due to the limited availability
339 of testing materials such as blood culture bottles among other factors. This limits the
340 capability to confirm the fact that common commensals could be responsible for some of the
341 true infections observed especially among immunocompromised individuals including
342 children. This in turn leaves them vulnerable to the BSIs of that origin. However, it is
343 recommended to employ appropriate policies to monitor and reduce the contamination levels
344 to less than 1% and enable avoidance of the associated consequences(32).

345 Antimicrobial Susceptibility Testing (AST) was variably done based on the availability of
346 testing materials. Each organism type was generally tested against at least 8 antibiotics except
347 for *Pseudomonas aeruginosa* and *Acinetobacter species*. However, the ratio of the individual
348 isolate to antibiotic tested was quite low (Refer to **Table 2**). This is similar to the observation
349 at Mulago hospital (33). This clearly shows the need for Uganda to improve in terms of supply
350 management and ensure the availability of necessary logistics for laboratory testing. For the
351 number of *S. aureus* isolates tested against Cefoxitin, 60% turned out resistant indicating a
352 possibility of high levels of MRSA in circulation. These (100%) being β -Lactamase producers,
353 they had already shown no response to Penicillin G. However, Gentamicin 74.1% (%S 95%
354 CI=53.4-88.1), Ciprofloxacin 55.2% (%S 95% CI=36.0-73.0), and Tetracycline 55% (%S 95%
355 CI=32.0-76.2) showed better activity against *S. aureus* compared to other agents.

356 *E. coli* and unspecified *coliforms* combined (n=22) showed relatively high levels of resistance
357 to commonly used antibiotics for empiric and targeted case management in the study setting
358 such as the third-generation Cephalosporins. They also showed 20% and 33.3% resistance to
359 Imipenem and Ertapenem respectively among the tested isolates. This indicates a possibility
360 of increasing resistance to the reserved options limiting the availability of better alternatives
361 when faced with cases of MDR pathogens. A similar feature was observed among the *Non-*
362 *Enterobacterales* although they were susceptible to Tetracycline. However, there were fewer
363 than 30 isolates for these two groups of organisms making it impossible to make appropriate
364 conclusions about their susceptibility patterns as guided by Clinical and Laboratory Standards
365 Institute (CLSI-M39A4E-2014) (29).

366 Data were scarce regarding the hospitalization of patients prior to sample collection. This was
367 observed in over 50% of the data. However, based on the available information, at least 37%
368 had their BSI being nosocomial. This is linked to the fact that they were exposed to the
369 hospital environment for more than 48 hours before being sampled for testing. This increases

370 the likelihood that the infection was acquired from the hospital making it necessary to
371 strengthen IPC measures observed in the facility before it is too late. Similar observations
372 were made elsewhere (2). However, higher levels of the same kind have been reported among
373 non-ICU hospitalized patients (8). The remaining 13% of the positive cases can be linked to
374 community-acquired infections. It is less than what is reported by other studies but there is
375 room for more (14, 21). This calls for the need to improve information management at the
376 testing and surveillance sites to enable capturing of all necessary data about the cases managed.
377 Further study might also be needed to identify the possible causes of the data incompleteness
378 at the different surveillance sites.

379

380 **Conclusions**

381 *S. aureus* is the most common organism responsible for bloodstream infections at this site.
382 There is a relatively high level of resistance to commonly used antibiotics among all
383 organisms. Currently, Gentamicin can be used to empirically manage suspected *S. aureus*
384 BSIs in this region. It is recommended to routinely utilize microbiology services with proper
385 data management to guide antimicrobial use and monitor blood culture contamination rates
386 and antimicrobial resistance trends to strengthen antimicrobial stewardship and surveillance
387 policies in the Eastern-Central region of Uganda.

388

389 **Acknowledgments**

390 The author appreciates all contribution from the administration and staff of Jinja Regional
391 Referral Hospital, especially the Children's ward, Nalufenya for the great work together with
392 Ms. Kasuswa Sophia, Mr. Kasibante Samuel, and Ms. Matinyi Sandra for the research

393 encouragement. The author thanks the Infectious Diseases Institute for the support to offer
394 microbiology services at this site.

395 **References**

- 396 1. Timsit J-F, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert
397 statement. *Intensive Care Medicine*. 2020;46(2):266-84.
- 398 2. Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C, et al. Epidemiology and Risk Factors
399 Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria.
400 *Open Forum Infectious Diseases*. 2020;7(11).
- 401 3. Duan N, Sun L, Huang C, Li H, Cheng B. Microbial Distribution and Antibiotic Susceptibility of Bloodstream
402 Infections in Different Intensive Care Units. *Front Microbiol*. 2021;12:792282.
- 403 4. Hussain MS, Basher H, Lone MS, Wani K. Bloodstream Infections in Pediatric Population in a Tertiary Care
404 Hospital. 2019.
- 405 5. NHSN. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line
406 Associated Bloodstream Infection) 2023 [updated 2023, January. Available from:
407 https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
- 408 6. CLSI. Principles and Procedures for Blood Cultures; Approved Guideline. CLSI document M47-A. Wayne, PA:
409 Clinical and Laboratory Standards Institute. 2007:110.
- 410 7. Sarkar S, Bhattacharyya A, Paria K. A Retrospective Study on Bacteria Causing Blood Stream Infection: Antibiotics
411 Resistance and Management. *Indian Journal of Pharmaceutical Sciences*. 2018;80(3):547-51.
- 412 8. Tian L, Zhang Z, Sun Z. Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in
413 China: a 20-year surveillance study (1998-2017). *Antimicrobial resistance & infection control*. 2019;8(1):1-8.
- 414 9. Bandy A, Almaeen AH. Pathogenic spectrum of blood stream infections and resistance pattern in Gram-negative
415 bacteria from Aljouf region of Saudi Arabia. *PLOS ONE*. 2020;15(6):e0233704.
- 416 10. Paul M, Bhatia M, Rekha US, Omar BJ, Gupta P. Microbiological Profile of Blood Stream Infections in Febrile
417 Neutropenic Patients at a Tertiary Care Teaching Hospital in Rishikesh, Uttarakhand. *Journal of Laboratory Physicians*.
418 2020;12(02):147-53.
- 419 11. Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu JB, et al. Bacteremia in febrile cancer
420 patients in Uganda. *BMC research notes*. 2019;12(1):1-6.


- 421 12. Zou Q, Zou H, Shen Y, Yu L, Zhou W, Sheng C, et al. Pathogenic Spectrum and Resistance Pattern of Bloodstream
422 Infections Isolated from Postpartum Women: A Multicenter Retrospective Study. *Infection and drug resistance*. 2021;14:2387.
- 423 13. Kisame R, Najjemba R, van Griensven J, Kitutu FE, Takarinda K, Thekkur P, et al. Blood culture testing outcomes
424 among non-malarial febrile children at antimicrobial resistance surveillance sites in Uganda, 2017–2018. *Tropical Medicine
425 and Infectious Disease*. 2021;6(2):71.
- 426 14. Myat TO, Oo KM, Mone HK, Htike WW, Biswas A, Hannaway RF, et al. A prospective study of bloodstream
427 infections among febrile adolescents and adults attending Yangon General Hospital, Yangon, Myanmar. *PLoS neglected
428 tropical diseases*. 2020;14(4):e0008268.
- 429 15. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A systematic review and meta-analysis of the
430 prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia. *Antimicrobial
431 agents and chemotherapy*. 2019;64(1):e01974-19.
- 432 16. Ombelet S, Kpossou G, Kotchare C, Agbobli E, Sogbo F, Massou F, et al. Blood culture surveillance in a secondary
433 care hospital in Benin: epidemiology of bloodstream infection pathogens and antimicrobial resistance. *BMC infectious
434 diseases*. 2022;22(1):1-15.
- 435 17. Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D. Microbial spectrum and drug-resistance profile of isolates
436 causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia. *Infection and drug
437 resistance*. 2018;11:1511-9.
- 438 18. Seni J, Mwakyoma A, Mashuda F, Marando R, Ahmed M, DeVinney R, et al. Deciphering risk factors for blood
439 stream infections, bacteria species and antimicrobial resistance profiles among children under five years of age in North-
440 Western Tanzania: a multicentre study in a cascade of referral health care system. *BMC pediatrics*. 2019;19(1):1-11.
- 441 19. Habyarimana T, Murenzi D, Musoni E, Yadufashije C, N Niyonzima F. Bacteriological Profile and Antimicrobial
442 Susceptibility Patterns of Bloodstream Infection at Kigali University Teaching Hospital. *Infection and drug resistance*.
443 2021;14:699-707.
- 444 20. AbuTaha SA, Al-Kharraz T, Belkebir S, Abu Taha A, Zyoud SeH. Patterns of microbial resistance in bloodstream
445 infections of hemodialysis patients: a cross-sectional study from Palestine. *Scientific Reports*. 2022;12(1):1-10.
- 446 21. Gezmu AM, Bulabula ANH, Dramowski A, Bekker A, Aucamp M, Souda S, et al. Laboratory-confirmed
447 bloodstream infections in two large neonatal units in sub-Saharan Africa. *International Journal of Infectious Diseases*.
448 2021;103:201-7.

- 449 22. Kokkayil P, Agarwal R, Mohapatra S, Bakshi S, Das B, Sood S, et al. Bacterial profile and antibiogram of blood
450 stream infections in febrile neutropenic patients with haematological malignancies. *The Journal of Infection in Developing*
451 *Countries*. 2018;12(06):442-7.
- 452 23. Yang S, Xu H, Sun J, Sun S. Shifting trends and age distribution of ESKAPEE_c resistance in bloodstream infection,
453 Southwest China, 2012–2017. *Antimicrobial Resistance & Infection Control*. 2019;8(1):1-10.
- 454 24. Semret M, Abebe W, Kong LY, Alemayehu T, Beyene T, Libman MD, et al. Prolonged empirical antibiotic therapy
455 is correlated with bloodstream infections and increased mortality in a tertiary care hospital in Ethiopia: bacteriology testing
456 matters. *JAC-antimicrobial resistance*. 2020;2(3):dlaa039.
- 457 25. Winsley TJ, Snape I, McKinlay J, Stark J, van Dorst JM, Ji M, et al. The ecological controls on the prevalence of
458 candidate division TM7 in polar regions. *Frontiers in microbiology*. 2014;5:345.
- 459 26. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.28th ed. CLSI guideline M100. Wayne, PA:
460 Clinical and Laboratory Standards Institute 2018.
- 461 27. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.30th ed. CLSI guideline M100. Wayne, PA:
462 Clinical and Laboratory Standards Institute. 2020.
- 463 28. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.31st ed. CLSI guideline M100. Wayne, PA:
464 Clinical and Laboratory Standards Institute. 2021.
- 465 29. CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Data; Approved Guideline-Fourth
466 Edition. CLSI guideline M39-A4. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.
- 467 30. Li Z, Zhuang H, Wang G, Wang H, Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to
468 methicillin-resistant *Staphylococcus aureus* in patients with malignancy: systemic review and meta-analysis. *BMC*
469 *infectious diseases*. 2021;21(1):1-10.
- 470 31. Kłos M, Pomorska-Wesołowska M, Romaniszyn D, Wójkowska-Mach J, Chmielarczyk A. Antimicrobial Resistance
471 in *Enterobacterales* Bacilli Isolated from Bloodstream Infection in Surgical Patients of Polish Hospitals. *International*
472 *Journal of Microbiology*. 2021;2021:6687148.
- 473 32. Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME, Weinstein MP, et al. Practical Guidance for Clinical
474 Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of
475 Methods for Addressing the Problem. *Clinical Microbiology Reviews*. 2019;33(1):e00009-19.


476 33. Chaplain D, Asutaku BB, Mona M, Bulafu D, Aruhomukama D. The need to improve antimicrobial susceptibility
477 testing capacity in Ugandan health facilities: insights from a surveillance primer. *Antimicrobial Resistance & Infection*
478 *Control*. 2022;11(1):1-7.

479


480



■ Significant ■ Contaminants ■ No Bacterial Growth



S.aureus-Resistant



PEN-Penicillin, FOX-Cefoxitin, GEN-Gentamicin, CIP-Ciprofloxacin, CLI-Clindamycin, ERY-

Erythromycin, CHL-Chloramphenicol, TCY-Tetracycline